18 citations
,
August 2024 in “eLife” JAK inhibition may help manage autoimmune conditions in Down syndrome.
April 2025 in “JAAD Case Reports” Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.
June 2025 in “Healthy-Mu Journal” The optimized Cinchonine gel effectively fights acne bacteria and is safe for twice-daily use.
1 citations
,
April 2025 in “Tropical Journal of Natural Product Research” Avicennia marina shows potential to treat Hepatitis C by targeting key proteins.
51 citations
,
October 2019 in “Cells” Baricitinib reduces inflammation and improves cell health in premature aging cells.
May 2025 in “Birth Defects Research” YWS1903 is safe for pregnant rats at moderate doses but causes fetal issues at high doses.
15 citations
,
November 2022 in “Cell Death and Disease” CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.
September 2013 in “Oncology Times” Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.
May 2025 in “Cellular Oncology” Blocking both P-cadherin and c-Met can effectively stop head and neck cancer growth.
11 citations
,
January 1997 in “Skin Pharmacology and Physiology” A certain inhibitor can slow down the decrease in DNA creation in mouse hair follicles, which might help with hair growth.
27 citations
,
February 2003 in “European Journal Of Oral Sciences” SVpgC2a cells show abnormal growth and keratin changes, modeling early cancer development.
The research found how certain drugs and polymers form stable complexes, which could help develop new pharmaceutical forms.
April 2023 in “Journal of Investigative Dermatology” Two new IRAK4-inhibitors effectively reduced skin inflammation and immune response markers in healthy volunteers.
19 citations
,
December 2015 in “European Journal of Human Genetics” A rare ITGB6 gene variant causes intellectual disability, hair loss, and dental issues.
56 citations
,
April 2019 in “The Plant Journal” Cyclic nucleotide-gated channels are crucial for proper root hair growth and calcium balance in plants.
91 citations
,
December 2019 in “The EMBO Journal” NEDD4 and NEDD4L help control intestinal stem cells and prevent tumors by breaking down the LGR5 receptor.
May 2025 in “CPT Pharmacometrics & Systems Pharmacology” A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.
23 citations
,
December 2013 in “Molecules” N13-substituted evodiamine derivatives improved anticancer activity and solubility, showing promise for drug development.
2 citations
,
July 2019 in “PLOS ONE” Certain genetic variations are linked to higher liver enzyme levels in patients treated for chronic hepatitis C with specific drugs.
3 citations
,
May 2025 in “Frontiers in Pharmacology” Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
November 2025 in “PubMed” Genetic variants in specific genes cause a type of hair loss.
14 citations
,
October 2003 in “Annals of Oncology” About half the patients treated with capecitabine and docetaxel developed severe hand-foot syndrome.
6 citations
,
March 2007 in “BioTechniques” PCR genotyping in cre-loxP mice can be inaccurate due to unintended gene deletions in non-target tissues.
ETS2 is crucial in squamous cell carcinoma development and could be a therapeutic target.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
1 citations
,
May 2025 in “Natural Products and Bioprospecting” PEVIII is a promising treatment for Pseudomonas aeruginosa keratitis.
10 citations
,
May 2020 in “Clinical and Experimental Health Sciences” Tideglusib may help bone regeneration without being toxic at low doses.
38 citations
,
April 2017 in “PLOS Genetics” GRHL3 is important for controlling gene activity in skin cells during different stages of their development.
5 citations
,
January 2024 in “Journal of Cancer” The treatment combination is effective and generally safe for lung cancer.
41 citations
,
December 2008 in “Journal of the American Academy of Dermatology” Oral valganciclovir improved a patient's skin condition caused by immunosuppression.